Synergistic effects of interferon-alpha in combination with chemoradiation on human pancreatic adenocarcinoma

World Journal of Gastroenterology

Volumn 11, Issue 10, 2005, Pages 1521-1528

  Ma, Jian Hua ^a   Patrut, Emilia ^a   Schmidt, Jan ^a   Knaebel, Hanns Peter ^a   Büchler, Markus W ^a   Märten, Angela ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Combination therapy; Interferon alpha; Pancreatic adenocarcinoma; Synergistic effects

Indexed keywords

ALPHA INTERFERON; ANNEXIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FAS ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARCINOMA CELL; CELL COUNT; CELL LINE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IMMUNOGENICITY; PANCREAS ADENOCARCINOMA; PREDICTION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; T LYMPHOCYTE;

EID: 16344376550     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i10.1521     Document Type: Article

References (26)

1. Raraty MG, Magee CJ, Ghaneh P, Neoptolemos JP. New techniques and agents in the adjuvant therapy of pancreatic cancer. Acta Oncol 2002; 41: 582-595
2. Picozzi VJ, Kozarek RA, Traverso LW. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 2003; 185: 476-480
3. Tsai JY, Iannitti DA, Safran H. Combined modality therapy for pancreatic cancer. Semin Oncol 2003; 30: 71-79
4. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr D, Büchler MW. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350: 1200-1210
5. Kirkwood J. Cancer immunotherapy: The interferon-alpha experience. Semin Oncol 2002; 29: 18-26
6. Belardelli F, Ferrantini M, Proietti E, Kirkwood JM. Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002; 13: 119-134
7. Gutterman JU. Cytokine therapeutics: Lessons from interferon alpha. Proc Natl Acad Sci USA 1994; 91: 1198-1205
8. Delcayre AX, Salas F, Mathur S, Kovats K, Lotz M, Lernhardt W. Epstein barr virus/ complement C3d receptor is an interferon alpha receptor. Embo J 1991; 10: 919-926
9. Mogensen KE, Lewerenz M, Reboul J, Lutfalla G, Uze G. The type I interferon receptor: structure, function, and evolution of a family business. J Interferon Cytokine Res 1999; 19: 1069-1098
10. Domanski P, Witte M, Kellum M, Rubinstein M, Hackett R, Pitha P, Colamonici OR. Cloning and expression of a long form of the beta subunit of the interferon alpha beta receptor that is required for signaling. J Biol Chem 1995; 270: 21606-21611
11. Iacopino F, Ferrandina G, Scambia G, Benedetti-Panici P, Mancuso S, Sica G. Interferons inhibit EGF-stimulated cell growth and reduce EGF binding in human breast cancer cells. Anticancer Res 1996; 16: 1919-1924
12. Pfeffer LM, Dinarello CA, Herberman RB, Williams BR, Borden EC, Bordens R, Walter MR, Nagabhushan TL, Trotta PP, Pestka S. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res 1998; 58: 2489-2499
13. Kurzrock R, Talpaz M, Guttermann J. Interferons: Clinical applications. Philadelphia: Lippincott; 1991
14. Holsti LR, Mattson K, Niiranen A, Standertskiold-Nordenstam CG, Stenman S, Sovijarvi A, Cantell K. Enhancement of radiation effects by alpha interferon in the treatment of small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 1987; 13: 1161-1166
15. Decatris M, Santhanam S, O'Byrne K. Potential of interferon-alpha in solid tumours: Part 1. BioDrugs 2002; 16: 261-281
16. Solorzano CC, Hwang R, Baker CH, Bucana CD, Pisters PW, Evans DB, Killion JJ, Fidler IJ. Administration of optimal biological dose and schedule of interferon alpha combined with gemcitabine induces apoptosis in tumor-associated endothelial cells and reduces growth of human pancreatic carcinoma implanted orthotopically in nude mice. Clin Cancer Res 2003; 9: 1858-1867
17. Wang L, Wu WZ, Sun HC, Wu XF, Qin LX, Liu YK, Liu KD, Tang ZY. Mechanism of interferon alpha on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice. J Gastrointest Surg 2003; 7: 587-594
18. Paquette RL, Hsu NC, Kiertscher SM, Park AN, Tran L, Roth MD, Glaspy JA. Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J Leukoc Biol 1998; 64: 358-367
19. Matikainen S, Sareneva T, Ronni T, Lehtonen A, Koskinen PJ, Julkunen I. Interferon-alpha activates multiple STAT proteins and upregulates proliferation-associated IL-2Ralpha, c-myc, and pim-1 genes in human T cells. Blood 1999; 93: 1980-1991
20. Marrack P, Kappler J, Mitchell T. Type I interferons keep activated T cells alive. J Exp Med 1999; 189: 521-530
21. El Sharouni SY, Kal HB, Battermann JJ. Accelerated regrowth of non-small-cell lung tumours after induction chemotherapy. Br J Cancer 2003; 89: 2184-2189
22. Davis AJ, Tannock JF. Repopulation of tumour cells between cycles of chemotherapy: A neglected factor. Lancet Oncol 2000; 1: 86-93
23. Correale P, Aquino A, Giuliani A, Pellegrini M, Micheli L, Cusi MG, Nencini C, Petrioli R, Prete SP, de Vecchis L, Turriziani M, Giorgi G, Bonmassar E, Francini G. Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA-A(*)02.01 restricted, CEA-peptide-specific cytotoxic T cells in vitro. Int J Cancer 2003; 104: 437-445
24. AbdAlla EE, Blair GE, Jones RA, Sue-Ling HM, Johnston D. Mechanism of synergy of levamisole and fluorouracil: induction of human leukocyte antigen class I in a colorectal cancer cell line. J Natl Cancer Inst 1995; 87: 489-496
25. Ohtsukasa S, Okabe S, Yamashita H, Iwai T, Sugihara K. Increased expression of CEA and MHC class I in colorectal cancer cell lines exposed to chemotherapy drugs. J Cancer Res Clin Oncol 2003; 129: 719-726
26. Zabel M, Weis J. Cell-specific regulation of the CD21 gene. Int Immunopharm 2001; 1: 483-493